Company profile: SciBase
1.1 - Company Overview
Company description
- Provider of medical devices leveraging Electrical Impedance Spectroscopy (EIS) to detect malignant melanoma and assess skin barrier function. Products include Nevisense, a point-of-care platform using EIS and AI for non-invasive melanoma detection and objective clinical decision-making, and Nevisense Go, a portable EIS device for detailed skin barrier assessment in research.
Products and services
- Nevisense: A point-of-care device using Electrical Impedance Spectroscopy (EIS) combined with AI to non-invasively detect melanoma and assess skin barrier, delivering objective data that supports clinical decision-making
- Electrical Impedance Spectroscopy (EIS): A non-invasive method that exploits tissue electrical property variations to categorize cellular structures and detect malignancies, forming SciBase’s diagnostic foundation across devices
- Nevisense Go: A portable research device utilizing EIS to analyze skin barrier properties in detail, enabling rigorous skin barrier assessment studies with precise, repeatable measurements for research applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SciBase
Spirogen
HQ: United Kingdom
Website
- Description: Provider of novel, sequence-selective DNA minor groove-binding molecules and proprietary pyrrolobenzodiazepine (PBD) technology, including PBD-based ADC payloads and PBD dimers that cross-link DNA to block replication and kill cancer stem cells. Offers licensing of PBD technology and research collaborations/partnerships to develop PBD-based ADCs designed to deliver potent anticancer agents to cancer cells for different cancer treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spirogen company profile →
Aegera Therapeutics
HQ: Canada
Website
- Description: Provider of clinical-stage targeted therapeutics addressing major unmet medical needs, with three programs in clinical development—two in oncology and one in neuropathic pain—and ongoing identification of novel development candidates based on core technologies. Part of Pharmascience Inc.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aegera Therapeutics company profile →
SmartHealth Dx
HQ: United States
Website
- Description: Provider of precision diagnostics addressing unmet clinical needs in vascular, metabolic, and oncological diseases, including SmartVascular Dx (blood test for vascular inflammation and stroke risk), SmartLung Dx (noninvasive test to identify benign lung nodules), SmartKidney Dx (metastasis risk in kidney disease), SmartScience Dx (~195,000-sample serum repository for biomarker discovery), and SmartPath Dx (real-time pathology imaging).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SmartHealth Dx company profile →
Theranostics Health
HQ: United States
Website
- Description: Provider of proteomics-based diagnostics and research services for drug development companies, developing diagnostic tests to enable personalized cancer therapies tailored to each patient’s tumor, utilizing Laser Capture Microdissection (LCM) and Reverse-phase Protein MicroArrays (RPMA) assays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theranostics Health company profile →
Ajax Therapeutics
HQ: United States
Website
- Description: Provider of therapies targeting cytokine signaling in hematologic malignancies, including AJ1-10502, a next-generation Type II JAK2 inhibitor for myeloproliferative neoplasms with improved efficacy and selectivity over Type I JAK2 inhibitors, and developer of a pipeline of selectively targeted small molecules via a partnership with Schrödinger using advanced computational chemistry and structure-based technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ajax Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SciBase
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SciBase
2.2 - Growth funds investing in similar companies to SciBase
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SciBase
4.2 - Public trading comparable groups for SciBase
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →